Document Detail

Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer.
MedLine Citation:
PMID:  16117607     Owner:  NLM     Status:  MEDLINE    
Preclinical studies have established that the polysaccharide fractions of Ganoderma lucidum have potential antitumor activity. Recent clinical studies have demonstrated that G. lucidum polysaccharides enhance host immune functions [e.g., enhanced natural killer (NK) cell activity] in patients with advanced solid tumors, although an objective response was not observed. This open-label study aimed to evaluate the effects of water-soluble G. lucidum polysaccharides (Ganopoly, Encore International Corp., Auckland, New Zealand) on immune functions in patients with advanced lung cancer. Thirty-six patients were enrolled and treated with 5.4 g/day Ganopoly for 12 weeks. In the 30 cancer patients who completed the trial, treatment with Ganopoly did not significantly alter the mean mitogenic reactivity to phytohemagglutinin, mean counts of CD3, CD4, CD8, and CD56, mean plasma concentrations of interleukin (IL)-2, IL-6, and interferon (IFN)-gamma, or NK activity in the patients, but the results were significantly variable. However, some cancer patients demonstrated markedly modulated immune functions. The changes in IL-1 were correlated with those for IL-6, IFN-gamma, CD3, CD8, and NK activity (P < .05), and IL-2 changes were correlated with those for IL-6, CD8, and NK activity. The results suggest that subgroups of cancer patients might be responsive to Ganopoly in combination with chemotherapy/radiotherapy. Further studies are needed to explore the efficacy and safety of Ganopoly used alone or in combination with chemotherapy/radiotherapy in lung cancer patients.
Yihuai Gao; Wenbo Tang; Xihu Dai; He Gao; Guoliang Chen; Jinxian Ye; Eli Chan; Hwee Ling Koh; Xiaotian Li; Shufeng Zhou
Related Documents :
6335357 - T gamma cell levels in mammary and cervical uterine cancer patients before and after lo...
21156337 - Prostate cancer antigen 3 score accurately predicts tumour volume and might help in sel...
22774387 - The females against cancer educational series: a qualitative evaluation of mother/daugh...
528067 - Aryl hydrocarbon hydroxylase inducibility in lung cancer patients undergoing radiotherapy.
205957 - Lumbar myelography with amipaque.
12237247 - Interactions between radiotherapy and endocrine therapy in breast cancer.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of medicinal food     Volume:  8     ISSN:  1096-620X     ISO Abbreviation:  J Med Food     Publication Date:  2005  
Date Detail:
Created Date:  2005-08-24     Completed Date:  2005-11-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9812512     Medline TA:  J Med Food     Country:  United States    
Other Details:
Languages:  eng     Pagination:  159-68     Citation Subset:  IM    
Institute of Food, Nutrition and Human Health, Massey University, New Zealand.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Antineoplastic Agents, Phytogenic / pharmacology,  therapeutic use*
Drugs, Chinese Herbal / pharmacology,  therapeutic use*
Immunity, Cellular / drug effects,  immunology
Killer Cells, Natural / drug effects,  immunology
Lung Neoplasms / drug therapy*,  immunology
Lymphocyte Activation / drug effects,  immunology
Lymphocyte Count
Lymphocyte Subsets
Middle Aged
Polysaccharides / pharmacology*,  therapeutic use
Reishi / chemistry*
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/Drugs, Chinese Herbal; 0/Polysaccharides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Enhancement of radioprotection and anti-tumor immunity by yeast-derived beta-glucan in mice.
Next Document:  Neuroprotective effects of butterbur and rough aster against kainic Acid-induced oxidative stress in...